BIIB Articles, Biogen Inc. - From 11/01/23

Biogen (NASDAQ:BIIB) has outperformed the market over the past 15 years by 1.68% on an annualized basis producing an average annual return of 12.42...

Amidst the fast-paced and highly competitive business environment of today, conducting comprehensive company analysis is essential for investors an...

Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV 76% Of Pa...

Biogen Inc. (NASDAQ: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) t...

Late-breaking Phase 1b data assesses the clinical outcomes of reducing tau in patients with early-stage Alzheimer's disease Additional late-...

Biogen (NASDAQ:BIIB) has outperformed the market over the past 20 years by 3.66% on an annualized basis producing an average annual return of 11.04...

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehe...

The U.S. Centers for Medicare and Medicaid Services has revised its policy permitting multiple uses of amyloid positron emission tomograp...

Blood tests for diagnosing Alzheimer's disease are eagerly awaited, but it may be a couple of years before they become a routine diagnostic too...

Hampus Hillerstrom, CEO of the Down syndrome research organization LuMind IDSC, is advocating for access to Alzheimer's drugs made by Eisa...